Xi'an Jiaotong University

About: Xi'an Jiaotong University is a education organization based out in Xi'an, China. It is known for research contribution in the topics: Heat transfer & Dielectric. The organization has 85440 authors who have published 99682 publications receiving 1579683 citations. The organization is also known as: '''Xi'an Jiaotong University''' & Xi'an Jiao Tong University.

Single-atom Rh/N-doped carbon electrocatalyst for formic acid oxidation.

Abstract: To meet the requirements of potential applications, it is of great importance to explore new catalysts for formic acid oxidation that have both ultra-high mass activity and CO resistance. Here, we successfully synthesize atomically dispersed Rh on N-doped carbon (SA-Rh/CN) and discover that SA-Rh/CN exhibits promising electrocatalytic properties for formic acid oxidation. The mass activity shows 28- and 67-fold enhancements compared with state-of-the-art Pd/C and Pt/C, respectively, despite the low activity of Rh/C. Interestingly, SA-Rh/CN exhibits greatly enhanced tolerance to CO poisoning, and Rh atoms in SA-Rh/CN resist sintering after long-term testing, resulting in excellent catalytic stability. Density functional theory calculations suggest that the formate route is more favourable on SA-Rh/CN. According to calculations, the high barrier to produce CO, together with the relatively unfavourable binding with CO, contribute to its CO tolerance. Atomically dispersed Rh on N-doped carbon exhibits 28- and 67-fold enhancements compared with state-of-the-art Pd/C and Pt/C, despite the low activity of Rh/C. The Rh single atoms exhibit high tolerance to CO poisoning compared to Rh nanoparticles.

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.

Abstract: Summary Background China has a high burden of hepatocellular carcinoma, and hepatitis B virus (HBV) infection is the main causative factor. Patients with hepatocellular carcinoma have a poor prognosis and a substantial unmet clinical need. The phase 2–3 ORIENT-32 study aimed to assess sintilimab (a PD-1 inhibitor) plus IBI305, a bevacizumab biosimilar, versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma. Methods This randomised, open-label, phase 2–3 study was done at 50 clinical sites in China. Patients aged 18 years or older with histologically or cytologically diagnosed or clinically confirmed unresectable or metastatic hepatocellular carcinoma, no previous systemic treatment, and a baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 were eligible for inclusion. In the phase 2 part of the study, patients received intravenous sintilimab (200 mg every 3 weeks) plus intravenous IBI305 (15 mg/kg every 3 weeks). In the phase 3 part, patients were randomly assigned (2:1) to receive either sintilimab plus IBI305 (sintilimab–bevacizumab biosimilar group) or sorafenib (400 mg orally twice daily; sorafenib group), until disease progression or unacceptable toxicity. Randomisation was done using permuted block randomisation, with a block size of six, via an interactive web response system, and stratified by macrovascular invasion or extrahepatic metastasis, baseline α-fetoprotein, and ECOG performance status. The primary endpoint of the phase 2 part of the study was safety, assessed in all patients who received at least one dose of study drug. The co-primary endpoints of the phase 3 part of the study were overall survival and independent radiological review committee (IRRC)-assessed progression-free survival according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 in the intention-to-treat population. The study is registered with ClinicalTrials.gov , NCT03794440 . The study is closed to new participants and follow-up is ongoing for long-term outcomes. Findings Between Feb 11, 2019 and Jan 15, 2020, we enrolled 595 patients: 24 were enrolled directly into the phase 2 safety run-in and 571 were randomly assigned to sintilimab–bevacizumab biosimilar (n=380) or sorafenib (n=191). In the phase 2 part of the trial, 24 patients received at least one dose of the study drug, with an objective response rate of 25·0% (95% CI 9·8–46·7). Based on the preliminary safety and activity data of the phase 2 part, in which grade 3 or worse treatment-related adverse events occurred in seven (29%) of 24 patients, the randomised phase 3 part was started. At data cutoff (Aug 15, 2020), the median follow-up was 10·0 months (IQR 8·5–11·7) in the sintilimab–bevacizumab biosimilar group and 10·0 months (8·4–11·7) in the sorafenib group. Patients in the sintilimab–bevacizumab biosimilar group had a significantly longer IRRC-assessed median progression-free survival (4·6 months [95% CI 4·1–5·7]) than did patients in the sorafenib group (2·8 months [2·7–3·2]; stratified hazard ratio [HR] 0·56, 95% CI 0·46–0·70; p Interpretation Sintilimab plus IBI305 showed a significant overall survival and progression-free survival benefit versus sorafenib in the first-line setting for Chinese patients with unresectable, HBV-associated hepatocellular carcinoma, with an acceptable safety profile. This combination regimen could provide a novel treatment option for such patients. Funding Innovent Biologics. Translation For the Chinese translation of the abstract see Supplementary Materials section.

PolarMask: Single Shot Instance Segmentation With Polar Representation

Abstract: In this paper, we introduce an anchor-box free and single shot instance segmentation method, which is conceptually simple, fully convolutional and can be used by easily embedding it into most off-the-shelf detection methods. Our method, termed PolarMask, formulates the instance segmentation problem as predicting contour of instance through instance center classification and dense distance regression in a polar coordinate. Moreover, we propose two effective approaches to deal with sampling high-quality center examples and optimization for dense distance regression, respectively, which can significantly improve the performance and simplify the training process. Without any bells and whistles, PolarMask achieves 32.9% in mask mAP with single-model and single-scale training/testing on the challenging COCO dataset. For the first time, we show that the complexity of instance segmentation, in terms of both design and computation complexity, can be the same as bounding box object detection and this much simpler and flexible instance segmentation framework can achieve competitive accuracy. We hope that the proposed PolarMask framework can serve as a fundamental and strong baseline for single shot instance segmentation task.

Preparation of 2D/2D g-C3N4 nanosheet@ZnIn2S4 nanoleaf heterojunctions with well-designed high-speed charge transfer nanochannels towards high-efficiency photocatalytic hydrogen evolution

Abstract: In this work, we design and construct a novel 2D/2D g-C 3 N 4 nanosheet@ZnIn 2 S 4 nanoleaf via a simple one-step surfactant-assisted solvothermal method for photocatalytic H 2 generation. Its unusual 2D/2D heterojunction structure provides far more contact areas and much faster charge transport rate than the 2D/0D heterojunction structure of g-C 3 N 4 nanosheet@ZnIn 2 S 4 microsphere. More importantly, this unique 2D/2D heterojunction leads the g-C 3 N 4 nanosheet@ZnIn 2 S 4 nanoleaf composite to generate numerous intimate high-speed charge transfer nanochannels in the interfacial junctions, and which could considerably enhance the photogenerated charge separation and migration efficiency, thus yielding a remarkable visible-light-driven H 2 evolution rate without the additive Pt cocatalyst (HER = 2.78 mmol h −1 g −1 ), nearly 69.5, 15.4, 8.2 and 1.9 times higher than that of pure g-C 3 N 4 nanosheet, pure ZnIn 2 S 4 microsphere, 2D/0D g-C 3 N 4 nanosheet@ZnIn 2 S 4 microsphere and pure ZnIn 2 S 4 nanoleaf, respectively. Additionally, the 2D/2D g-C 3 N 4 nanosheet@ZnIn 2 S 4 nanoleaf exhibits an outstanding stability and recyclability, manifesting a promising potential application in sustainable energy conversion. This work would provide a platform for the design and synthesis of binary heterojunction composite system with highly-efficient charge separation and transfer.

Dementia in China: epidemiology, clinical management, and research advances

Abstract: China has the largest population of patients with dementia in the world, imposing a heavy burden on the public and health care systems. More than 100 epidemiological studies on dementia have been done in China, but the estimates of the prevalence and incidence remain inconsistent because of the use of different sampling methods. Despite improved access to health services, inadequate diagnosis and management for dementia is still common, particularly in rural areas. The Chinese Government issued a new policy to increase care facilities for citizens older than 65 years, but most patients with dementia still receive care at home. Western medicines for dementia symptoms are widely used in China, but many patients choose Chinese medicines even though they have little evidence supporting efficacy. The number of clinical trials of Chinese and western medicines has substantially increased as a result of progress in research on new antidementia drugs but international multicentre studies are few in number. Efforts are needed to establish a national system of dementia care enhance training in dementia for health professionals, and develop global collaborations to prevent and cure this disease.